Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4394 in prostate cancer
NCT06783829Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-4394 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui. Primary endpoints: Dose-limiting toxicity at 3 weeks, Maximal tolerable dose at 3 weeks and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
SHR-4394
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06783829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783829.